Overview
Chemicals

New Japan Chemical Co.,Ltd.

Shin Nihon Rika is a specialty chemical manufacturer focused on oleochemicals and petrochemical-based products. Its core product portfolio includes fatty acids, higher alcohols, unsaturated alcohols, surfactants (derived from natural fats and oils), as well as plasticizers, functional products, and resin additives (derived from petrochemical raw materials). The company serves markets including plastics, coatings, lubricants, and cosmetics, and operates through a group comprising the parent company, six subsidiaries, and four affiliates, with manufacturing presence extending to Malaysia via Edenor Oleochemicals Rika (M) Sdn. Bhd.

Market Cap
¥8.13B
US$51.8M
EV
¥1.50B
US$9.54M
Stock¥218▼-0.91%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
0.7
x
LTM EV/EBIT
0.2
x
LTM PER
6.0
x
LTM PBR
0.4
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-24.4%pt
100123
Oct 24, 25 – Oct 23, 26StockTOPIX
1Dec 3, 25Downward revision due to ¥740M loss on Sakai plant disposal
2Dec 5, 25Adjustment selling after Sakai plant disposal loss
3Aug 10, 26Q1 earnings: net profit +290% YoY, FY guidance raised (operating profit 2.6x)
MC → EV Bridge
8.13BUS$51.8MMarket Cap6.95BUS$44.3M+ Debt4.31BUS$27.5M− Cash10.5BUS$67.1M− Inv. Sec.1.25BUS$7.98M+ NCI1.50BUS$9.54MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
32.4US$206M'22/333.1US$211M'23/332.9US$210M'24/332.7US$209M'25/332.1US$205M'26/3
EBITDA 5Y (¥B)
1.97US$12.6M'22/30.27US$1.73M'23/31.10US$7.03M'24/31.62US$10.3M'25/31.33US$8.49M'26/3
Net Income 5Y (¥B)
0.81US$5.17M'22/3-0.44-US$2.83M'23/30.22US$1.40M'24/30.52US$3.33M'25/30.60US$3.81M'26/3
Capital Structure
75%
25%
EquityD/E 0.34xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
11.6US$73.9M9.96US$63.5M'22/312.1US$77.2M10.2US$64.8M'23/314.0US$89.0M7.58US$48.4M'24/312.9US$82.2M7.29US$46.5M'25/316.2US$103M7.40US$47.2M'26/3
Shareholders
Top 10 hold 36.3%
1
YMC Co., Ltd.
14.76%
2
Resona Bank, Limited
4.99%
3
FUKUDA DENSHI CO.,LTD.
3.22%
4
STATE STREET BANK AND TRUST COMPANY 505103 (Standing Proxy: Mizuho Bank, Ltd.)
2.39%
5
Nomura Trading Co., Ltd.
2.28%
6
Daiso Chemical Co., Ltd.
2.04%
7
NOF CORPORATION
1.87%
8
Mitsui Sumitomo Insurance Company, Limited
1.77%
9
KH Neochem Co.,Ltd.
1.63%
10
IWATANI CORPORATION
1.37%
Management
7 officers
Yoshiki MIURA
Representative Director, Chairman and Executive Officer
Apr 1978 Joined Toyota Tsusho Corporation Jul 2001 President, Toyota Tsusho Australasia Apr 2004 Vice President, Toyota Tsusho America Jun 2012 Managing Director, Toyota Tsusho Corporation Apr 2015 Senior Managing Director, Toyota Tsusho Corporation Jun 2019 Director, Managing Executive Officer, in charge of Sales Division, the Company Jun 2020 Representative Director, President and Executive Officer, the Company Apr 2022 Representative Director, President and Executive Officer, Head of R&D Division and General Manager, New Business Planning Office, the Company Aug 2022 Outside Director, ISE Holdings Co., Ltd. (current) Apr 2023 Representative Director, President and Executive Officer, General Manager, New Business Planning Office, the Company Apr 2024 Representative Director, President and Executive Officer, the Company Apr 2025 Representative Director, Chairman and Executive Officer, the Company (current)
1955-05-07
Kayoko MORITA
Representative Director, President and Executive Officer, in charge of R&D Division
Apr 1990 Joined the Company Apr 2014 General Manager, Accounting Department, the Company Apr 2018 General Manager, Administration Division and General Manager, Intellectual Property Department, the Company Apr 2020 Executive Officer, General Manager, Corporate Planning and Administration Division, the Company Apr 2022 Executive Officer, General Manager, Sales Division, the Company Jun 2023 Director, Executive Officer, General Manager, Sales Division, the Company Jun 2024 Director, Managing Executive Officer, General Manager, Sales Division, the Company Apr 2025 Representative Director, President and Executive Officer, the Company Apr 2026 Representative Director, President and Executive Officer, in charge of R&D Division, the Company (current)
1967-09-19
Keiji MATSUMOTO
Director (Note 1)
Mar 1971 Joined House Foods Corporation (now House Foods Group Inc.) Jun 1998 Director, House Foods Corporation Apr 2012 Representative Director, House Foods Corporation Oct 2013 Representative Director, Senior Managing Director, House Foods Corporation Mar 2015 Chairman, Vokes Trading Co., Ltd. Apr 2018 Director, House Foods Holding USA, Inc. Jun 2022 Director, the Company (current)
1949-03-01
Yasuyuki KAWAHARA
Director (Full-time Audit and Supervisory Committee Member)
Apr 1992 Joined the Company Jun 2012 General Manager, Technology Development Department, the Company Apr 2014 Executive Officer, General Manager, Functional Chemicals Business Division, the Company Jun 2016 Director, Executive Officer, General Manager, Functional Chemicals Business Division, the Company Apr 2021 Director, Executive Officer, Executive Fellow, R&D Division, the Company Jun 2023 Director (Full-time Audit and Supervisory Committee Member), the Company (current)
1967-10-01
Mitsuhiro TAKEBAYASHI
Director (Audit and Supervisory Committee Member) (Note 1)
Oct 1996 (description not provided in source) Jul 2000 (description not provided in source) Sep 2006 Joined Aoyama Audit Corporation; Registered as Certified Public Accountant; Opened Takebayashi Certified Public Accountant Office Nov 2007 Founded Proactive Co., Ltd., Representative Director (current) Mar 2009 (description not provided in source) Jun 2016 Outside Director, Silex Technology, Inc.; Outside Director, Metal Art Co., Ltd. Jun 2020 Director (Audit and Supervisory Committee Member), the Company (current) Jun 2026 Outside Director, Denkyo Group Holdings Co., Ltd.
1967-02-23
Masafumi SUGIMOTO
Director (Note 1)
Apr 1984 Joined Takeda Pharmaceutical Company Limited Oct 2009 President, Healthcare Company, Takeda Pharmaceutical Company Limited Apr 2017 Representative Director, President, Takeda Consumer Healthcare Co., Ltd. (now Alinamin Pharmaceutical Co., Ltd.) Jun 2019 Representative Director, President, Rohto Pharmaceutical Co., Ltd. Aug 2021 Representative Director, Chairman, Tenfuji Pharmaceutical Co., Ltd. (current) Jul 2025 Executive Advisor, Rohto Group (scheduled to retire Jun 2026) Jun 2026 Director, the Company (scheduled) Jul 2026 Management Strategy Advisor, Rohto Pharmaceutical Co., Ltd.
1961-08-24
Hiroshi YAMAHATA
Director (Audit and Supervisory Committee Member) (Note 1)
Oct 2002 Registered as attorney; joined Miyake Law Office May 2012 Partner, Miyake Law Office (current) Apr 2017 Visiting Professor, Graduate School of Law, Doshisha University (current) Jun 2017 Outside Audit & Supervisory Board Member, Hinode Securities Co., Ltd. (now Naito Securities Co., Ltd.) Dec 2019 Outside Director, Tsucell Co., Ltd. Jun 2026 Director (Audit and Supervisory Committee Member), the Company
1976-10-09
Large Shareholding Reports
YMC Co., Ltd.
2026-10-08
12.44%→11.38%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-09-30
13.55%→12.44%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-09-11
14.70%→13.55%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-04-23
15.76%→14.70%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-03-26
16.81%→15.76%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-03-06
18.06%→16.81%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-02-27
19.32%→18.06%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-02-20
20.51%→19.32%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-02-10
21.96%→20.51%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2026-01-29
23.25%→21.96%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2025-10-31
22.20%→23.25%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2025-08-12
21.15%→22.20%
Annual report (as of 2026-03-31): 14.76%
YMC Co., Ltd.
2025-07-31
20.14%→21.15%
Annual report (as of 2026-03-31): 14.76%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-10-08
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-11
Large Shareholding Report
TDnet
2026-08-07
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-23
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-04-23
Large Shareholding Report
EDINET
2026-03-26
Large Shareholding Report
EDINET
2026-03-06
Large Shareholding Report
EDINET
2026-02-27
Large Shareholding Report
EDINET
2026-02-20
Large Shareholding Report
TDnet
2026-02-13
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2026-02-10
Large Shareholding Report
EDINET
2026-01-29
Large Shareholding Report
EDINET
2025-11-13
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2025-10-31
Large Shareholding Report
EDINET
2025-08-12
Large Shareholding Report
TDnet
2025-08-08
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-07-31
Large Shareholding Report
EDINET
2025-06-23
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-13
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-13
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-09
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-27
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-09
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-09
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-29
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-09
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-10
Quarterly Securities Report
EDINET
2022-08-05
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →